Amgen prevented Regeneron from competing on a level playing field and unfairly denied patients access to Praluent. This anticompetitive practice shut out an innovative therapy from the PCSK9 ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...

Cantor Fitzgerald upgraded Regeneron (REGN) to Overweight from Neutral with a price target of $695, down from $800, as the analyst took over coverage of the stock. Published first on TheFly ...

Meacham argues Regeneron's Eylea franchise and melanoma pipeline optionality leave it well-positioned, raising his price target to $700 from $600 after a roughly 55% stock pullback since last year ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Truist lowered the firm’s price target on Regeneron (REGN) to $975 from $1,004 and keeps a Buy rating on the shares. The firm notes Regeneron has pulled back over the last few quarters on Eylea ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy. As of May 6, 2025, the average one-year price target for ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug ...

April 22 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially ...